Johnson & Johnson (J&J) has reported new outcomes from the Phase II RedirecTT-1 trial of bispecific antibodies, Talvey and ...

Genmab has reported new outcomes from the Phase Ib/II EPCORE NHL-2 trial Arm 10 of T-cell engaging bispecific antibody, ...

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population.

Novartis has reported positive outcomes from the multicentre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan).

At the CTO West Coast conference, experts discussed the future of oncology clinical trials and key themes surrounding them.

At a panel at CTO West Coast, experts from biopharmaceutical companies outlined innovative strategies to shape the future of ...

MSD has begun the randomised MOBILIZE-1 Phase III trial to assess the investigational quadrivalent vaccine, V181.

HepaRegeniX has begun dosing subjects in a Phase Ib trial of HRX-215 in subjects undergoing partial liver resection due to ...

The relationship between neurodegenerative conditions and late-life mood disorders (LLMDs) is largely unexplored.

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582.

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

NewAmsterdam Pharma has reported encouraging topline data from a prespecified biomarker analysis of Alzheimer’s disease in a ...